588 related articles for article (PubMed ID: 17362051)
1. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
Fleischmann R; Iqbal I
Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
[TBL] [Abstract][Full Text] [Related]
2. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
3. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
4. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
Wiedmann MW; Mössner J; Baerwald C; Pierer M
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
[TBL] [Abstract][Full Text] [Related]
5. The safety of anti-TNF agents in the elderly.
Migliore A; Bizzi E; Laganà B; Altomonte L; Zaccari G; Granata M; Canzoni M; Marasini B; Massarotti M; Massafra U; Ranieri M; Pilla R; Martin LS; Pezza M; Vacca F; Galluccio A
Int J Immunopathol Pharmacol; 2009; 22(2):415-26. PubMed ID: 19505394
[TBL] [Abstract][Full Text] [Related]
6. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
7. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
10. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
11. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
12. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
13. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
14. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
Kaltsonoudis E; Zikou AK; Voulgari PV; Konitsiotis S; Argyropoulou MI; Drosos AA
Arthritis Res Ther; 2014 Jun; 16(3):R125. PubMed ID: 24938855
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
[TBL] [Abstract][Full Text] [Related]
17. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
[TBL] [Abstract][Full Text] [Related]
19. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
[TBL] [Abstract][Full Text] [Related]
20. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]